L
Linda M. Liau
Researcher at University of California, Los Angeles
Publications - 288
Citations - 27770
Linda M. Liau is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Glioma & Immunotherapy. The author has an hindex of 72, co-authored 258 publications receiving 23933 citations. Previous affiliations of Linda M. Liau include University of California & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang,David W. White,Stefan Gross,Bryson D. Bennett,Mark A. Bittinger,Edward M. Driggers,Valeria Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin Marks,Robert M. Prins,Patrick S. Ward,Katharine E. Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Matthew G. Vander Heiden,Shinsan M. Su +20 more
TL;DR: It is shown that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG), and that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
Journal ArticleDOI
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Ingo K. Mellinghoff,Maria Y. Wang,Igor Vivanco,Daphne A. Haas-Kogan,Shaojun Zhu,Ederlyn Q. Dia,Kan V. Lu,Koji Yoshimoto,Julie H. Y Huang,Dennis J. Chute,Bridget L. Riggs,Steve Horvath,Linda M. Liau,Webster K. Cavenee,P. Nagesh Rao,Rameen Beroukhim,Rameen Beroukhim,Rameen Beroukhim,Timothy C. Peck,Timothy C. Peck,Timothy C. Peck,Jeffrey C. Lee,Jeffrey C. Lee,Jeffrey C. Lee,William R. Sellers,William R. Sellers,William R. Sellers,David Stokoe,Michael D. Prados,Timothy F. Cloughesy,Charles L. Sawyers,Paul S. Mischel +31 more
TL;DR: Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors, and effects of the molecular abnormalities in vitro are identified.
Journal ArticleDOI
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim,Gad Getz,Leia Nghiemphu,Jordi Barretina,Teli Hsueh,David Linhart,Igor Vivanco,Jeffrey C. Lee,Julie H. Huang,Sethu Alexander,Jinyan Du,Tweeny R Kau,Roman K. Thomas,Kinjal Shah,Horacio Soto,Sven Perner,John R. Prensner,Ralph M. Debiasi,Francesca Demichelis,Charlie Hatton,Mark A. Rubin,Levi A. Garraway,Stan F. Nelson,Linda M. Liau,Paul S. Mischel,Timothy F. Cloughesy,Matthew Meyerson,Todd Golub,Eric S. Lander,Ingo K. Mellinghoff,William R. Sellers +30 more
TL;DR: A systematic method, called Genomic Identification of Significant Targets in Cancer (GISTIC), designed for analyzing chromosomal aberrations in cancer, is used to study gliomas and the results support the feasibility and utility of systematic characterization of the cancer genome.
Journal ArticleDOI
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas,Alissa C. Baker,Ralph M. Debiasi,Ralph M. Debiasi,Wendy Winckler,Wendy Winckler,Thomas LaFramboise,Thomas LaFramboise,William M. Lin,William M. Lin,Meng Wang,Meng Wang,Whei Feng,Whei Feng,Thomas Zander,Laura E. MacConnaill,Laura E. MacConnaill,Jeffrey C. Lee,Jeffrey C. Lee,Rick Nicoletti,Rick Nicoletti,Charlie Hatton,Charlie Hatton,Mary Goyette,Luc Girard,Kuntal Majmudar,Liuda Ziaugra,Kwok-Kin Wong,Stacey Gabriel,Rameen Beroukhim,Rameen Beroukhim,Michael Peyton,Jordi Barretina,Jordi Barretina,Amit Dutt,Amit Dutt,Caroline Emery,Heidi Greulich,Heidi Greulich,Kinjal Shah,Kinjal Shah,Hidefumi Sasaki,Adi F. Gazdar,John D. Minna,Scott A. Armstrong,Ingo K. Mellinghoff,F. Stephen Hodi,Glenn Dranoff,Paul S. Mischel,Timothy F. Cloughesy,Stan F. Nelson,Linda M. Liau,Kirsten D. Mertz,Kirsten D. Mertz,Mark A. Rubin,Holger Moch,Massimo Loda,William J. Catalona,Jonathan A. Fletcher,Sabina Signoretti,Frederic J. Kaye,Kenneth C. Anderson,George D. Demetri,Reinhard Dummer,Stephan N. Wagner,Meenhard Herlyn,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Levi A. Garraway,Levi A. Garraway +71 more
TL;DR: High-throughput genotyping is adapted to query 238 known oncogene mutations across 1,000 human tumor samples and established robust mutation distributions spanning 17 cancer types, offering a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time'.
Journal ArticleDOI
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy,Aaron Mochizuki,Joey Orpilla,Willy Hugo,Alexander Lee,Tom B. Davidson,Anthony C. Wang,Benjamin M. Ellingson,Julie A. Rytlewski,Catherine Sanders,Eric S. Kawaguchi,Lin Du,Gang Li,William H. Yong,Sarah C. Gaffey,Adam L. Cohen,Ingo K. Mellinghoff,Eudocia Q. Lee,David A. Reardon,Barbara O’Brien,Nicholas Butowski,Phioanh L. Nghiemphu,Jennifer Clarke,Isabel Arrillaga-Romany,Howard Colman,Thomas Kaley,John de Groot,Linda M. Liau,Patrick Y. Wen,Robert M. Prins +29 more
TL;DR: It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.